03/15/23 8:30 AMNasdaq : JAGX low floatJaguar Health Celebrates U.N. International Day of Forests with Milestone of Providing Income to 20,000+ People Living in Tropical Rainforest CommunitiesMarch 15,RHEA-AIvery positive
03/13/23 8:30 AMNasdaq : JAGX low floatJaguar Health Leveraging AI to Support Patient Access to Mytesi, the Company's FDA-Approved Prescription DrugJaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar" or the "Company") today announced that the Company is developing an artificialRHEA-AIneutral
03/02/23 8:30 AMNasdaq : JAGX conferenceslow floatJaguar Health to Present at BioTrinity 2023 Conference’s R&D Spotlight on Rare DiseasesPresentation will cover Jaguar and Napo Therapeutics' focus on development and commercialization of crofelemer for short bowel syndrome (SBS) and congenital diarrheal disorders (CDD) Crofelemer has received orphan drug designation from the FDA and the European Medicines Agency for both SBS and aRHEA-AIneutral
02/28/23 8:30 AMNasdaq : JAGX low floatFDA Grants Orphan Drug Designation to Jaguar Health for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication in the USJaguar Health (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug DesignationRHEA-AIvery positive
02/23/23 8:30 AMNasdaq : JAGX fda approvallow floatJaguar Health Receives Notice of Allowance for U.S. Patent for Lead FDA Approved Drug CrofelemerJaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark OfficeRHEA-AIneutral
02/21/23 8:30 AMNasdaq : JAGX clinical triallow floatJaguar Health Achieves Approximately 75% Enrollment in Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related DiarrheaRHEA-AIvery positive
02/09/23 8:30 AMNasdaq : JAGX low floatJaguar Health Announces Initial Close in Private Placement Financing Round for Napo Therapeutics S.p.A.This closing on funds from SPRIM Global Investments, a healthcare-focused international venture capital firm, was completed at a fully diluted valuation of approximately €55 million Jaguar currently owns approximately 73.5% of Napo Therapeutics Napo Therapeutics' mission is to provide access toRHEA-AIneutral
02/08/23 8:30 AMNasdaq : JAGX low floatJaguar Health Regains Compliance with Nasdaq’s Bid Price RequirementJaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on February 7, 2023 the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") that Jaguar hasRHEA-AIneutral
02/01/23 9:45 AMNasdaq : JAGX low floatJaguar Health & SynWorld Technologies Mutually Agree to Terminate License and Commercialization Agreement for Canalevia for Treatment of Diarrhea in Dogs in China Given Jaguar’s 2023 Focus on Human Drug DevelopmentJaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") and SynWorld Technologies Corporation (SynWorld) todayRHEA-AIneutral
02/01/23 8:30 AMNasdaq : JAGX low floatJaguar Health Engages Shareholder Intelligence Services, LLC (ShareIntel) to Monitor Trading Activity in Effort to Identify Possible Illegal Short SellingJaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that it has entered into a service agreement with Shareholder Intelligence Services, LLC ( ShareIntel), a leading compliance driven SAAS platform, to track marketRHEA-AInegative